Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin Add-on to Entecavir in Chronic Hepatitis B
NCT04182321Completed
- Start
- Mar 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of liquid metformin (Aspargo Labs) in Chronic Hepatitis B (CHB) (2 arms). Primary endpoint: Serum Hepatitis B Surface Antigen Level at 36 weeks. Started Mar 2020; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04182321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182321.